Otezla (apremilast) is Amgen’s oral PDE4 inhibitor for plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease. Per its DailyMed label, revised December 2025, the maintenance dose is 30 mg twice daily, or 75 mg once daily for the extended-release Otezla XR, which is why a 30-day supply is 60 tablets and why the monthly number is so large.
The unusual thing about Otezla’s price in 2026 is that two big changes have been announced and neither one has reached the pharmacy counter. Generic apremilast is FDA approved but not for sale. Medicare negotiated a price 65% below list, but it starts in 2027 and covers Part D only. Everything below was pulled and verified on September 2, 2026, and this page covers cost and navigation, not treatment decisions.
What Does Otezla Cost Without Insurance?
Retail figures come from SingleCare’s live Otezla page (updated September 2, 2026) and SingleCare’s own explainer article (updated February 23, 2026), both for 60 of the 30 mg tablets. Acquisition cost comes from CMS’s National Average Drug Acquisition Cost survey, effective August 19, 2026 and current as of September 2, 2026. The list price and negotiated price come from CMS’s own negotiation fact sheet.
| Price point (30-day supply) | Low | Average / typical | High |
|---|---|---|---|
| Retail cash, no discount card | $6,843 | $6,843 to $6,928 | $6,927.54 |
| Cash with a discount card | $5,133.82 | $5,134 | $5,134 |
| CMS NADAC acquisition cost, 60 x 30 mg | $5,432.89 | $5,432.89 | $5,432.89 |
| CMS NADAC acquisition cost, Otezla XR 75 mg | $5,430.58 | $5,430.58 | $5,430.58 |
| List price recorded by CMS for 2024 | $4,722 | $4,722 | $4,722 |
| Medicare negotiated price from Jan 1, 2027 | $1,650 | $1,650 | $1,650 |
| Otezla Co-Pay Program (commercial insurance only) | $0 | $0 | $0 |
| Amgen Safety Net Foundation (income-qualified) | $0 | $0 | $0 |
Two numbers frame the honest answer. If you walk in with nothing, expect roughly $6,843 to $6,928. If you run a discount card, expect about $5,134. The two SingleCare pages we read disagree by about $85 on the retail figure and agree to the dollar on the card price, which they both attribute to Kroger. Named-chain prices move between sessions, so treat the chain name as illustrative and the band as the real answer.
The list price and the counter price disagree, and both are right
CMS’s negotiation fact sheet records Otezla’s list price for a 30-day supply at $4,722 in calendar year 2024. CMS’s acquisition-cost survey puts what pharmacies pay in August 2026 at $90.54823 per 30 mg tablet, which is $5,432.89 for 60. Otezla XR works out to almost exactly the same monthly figure, $181.01929 per 75 mg tablet, or $5,430.58 for 30 days.
The $711 gap between the 2024 list figure and the 2026 acquisition figure is two years of price increases, not a contradiction. The further $1,400 to $1,500 gap up to the retail quote is pharmacy markup. State the vintage whenever you quote any of these back to a pharmacy, because they are not the same measurement.
The generic that exists on paper and nowhere else
This is the part worth understanding before you assume you can just ask for the cheap version. FDA’s Orange Book shows apremilast tablets in 10, 20 and 30 mg from Mankind Pharma approved February 7, 2024 under ANDA 211734, with an AB therapeutic equivalence rating, and several other manufacturers hold approvals of their own.
None of them are being sold. As of FDA’s August 28, 2026 update, no generic apremilast appears in the agency’s directory of marketed drug products, where only Amgen’s Otezla listings show up. CMS’s national acquisition survey, current September 2, 2026, has no apremilast rows at all, which it would if pharmacies were buying and dispensing one. And Otezla’s eligibility for Medicare negotiation rests on it being a single source drug without generic competition. SingleCare’s explainer puts the likely U.S. arrival at 2028.
So if a pharmacy or a price site tells you a generic is available, ask them to quote you an NDC. As of September 2026 there is not one to fill.
What Drives the Price
The absent generic. Approved but unlaunched generics do nothing for your bill. Until one actually ships, there is no substitution to request and no price competition to benefit from.
Whether a discount card gets applied. The swing between average retail and the card price is about $1,700 to $1,800 a month on the identical bottle. It is the largest lever available to a cash payer with no program.
Your insurance type rather than your income. Amgen’s co-pay program covers commercially insured patients regardless of income level, and excludes government-subsidized plans. The free-drug foundation runs the opposite way, requiring financial need and limited coverage. Which door is open to you is decided by your card, not your paycheck.
Brand strategy and the Medicare clock. Otezla is one of the 15 drugs in the second Medicare negotiation cycle, and its price for Part D drops to $1,650 on January 1, 2027, a 65% cut from the recorded 2024 list price. That is a large discount by any measure and it will not touch a cash payer’s receipt.
Which product you are on. Otezla and Otezla XR price out within $3 a month of each other at acquisition cost, so the choice between twice-daily tablets and the once-daily extended-release version is not a cost decision.
Cash Price vs. Insurance
For a commercially insured patient, the manufacturer program is straightforwardly the best deal. Amgen advertises as little as $0 out of pocket per month when enrolled in the Otezla Co-Pay Program, available to patients with commercial insurance usually purchased individually or through an employer, regardless of income level. The benefit applies against deductible, coinsurance and copayment, is capped by an annual maximum, and requires re-enrollment at intervals.
For anyone on Medicare or Medicaid, that card is closed. Amgen instead points Medicare beneficiaries toward Extra Help, the Part D low-income subsidy, through its Amgen SupportPlus service. Starting January 1, 2027, Part D enrollees also get the benefit of the $1,650 negotiated price, which changes what plans pay and flows through to cost sharing.
For an uninsured patient, cash at $5,134 to $6,928 a month is a number very few households can carry, and there is no reason to treat it as the plan. The realistic target is $0 through the Amgen Safety Net Foundation. If a pharmacy quotes you something well outside the band above, our fair price checker is a fast way to test it before paying.
How to Pay Less
-
Apply to the Amgen Safety Net Foundation first. It is a nonprofit patient assistance program sponsored by Amgen that provides qualifying patients Amgen medicines at no cost. The published 2026 household income guidelines run from $47,880 to $79,800 for a household of one and from $99,000 to $165,000 for a household of four, depending on which guideline applies, with limits roughly 25% higher in Alaska and 15% higher in Hawaii. You must have lived in the U.S. or its territories for six months or longer.
-
Enroll in the Otezla Co-Pay Program if you have commercial insurance. Amgen states eligible patients may pay as little as $0 a month regardless of income, and notes that re-enrollment is required at regular intervals. Diary the renewal date, because a lapsed enrollment turns a $0 fill into a four-figure one.
-
Run a discount card on every fill, even a bridge fill. Both SingleCare pages we read put the floor at $5,134 against a $6,843 to $6,928 retail average. Our comparison of GoodRx vs. SingleCare covers how to check both cards on the same NDC quickly.
-
Ask a 340B community health center what it can dispense. Federally funded health centers buy outpatient drugs at discounted statutory prices and charge on a sliding scale tied to income. Our guide to free and sliding-scale clinics explains how to find one and what to ask when you call.
-
If you are on Medicare, check Extra Help and mark January 2027. Amgen’s own page routes Medicare patients to the Part D low-income subsidy, and the negotiated $1,650 price takes effect at the start of 2027. Those two together are the Medicare version of this list.
-
Do not let the dermatology and rheumatology bills pile up separately. A dermatologist visit without insurance has its own cash price, and if a specialist bill has already landed, our medical bill negotiation guide covers what to say before you pay it.
Bottom Line
Budget $5,134 to $6,928 for a 30-day supply of Otezla if you pay cash in September 2026, with a discount card putting you at the low end and no card putting you at the high end. CMS data shows pharmacies acquiring the drug for $5,432.89 a month, and CMS recorded a $4,722 list price for 2024.
Two things people expect to save them will not, at least not yet. Generic apremilast is approved and AB-rated but is not being sold anywhere in the U.S. as of September 2026, with 2028 the commonly cited arrival. Medicare’s negotiated $1,650 price is real and takes effect January 1, 2027, but it is a Part D price and does nothing for a cash payer. Until then, the Amgen Safety Net Foundation is the route that actually reaches $0 for someone without insurance.
For other immunology prescriptions priced this way, see our guides to Rinvoq, Skyrizi, Tremfya and Dupixent. Humira shows what actually happens to a price like this one when cheaper equivalents finally reach the shelf, which is the outcome apremilast is still waiting on.